SCHEMBL7714685

SCHEMBL7714685

CCCC(CP(=O)(O)O)C(CC)C(=O)OCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 2/20 0.42
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
FDPS P14324 6/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 2/20 0.31
CHRM1 P11229 1/20 0.31
AKR1A1 P14550 1/20 0.31
CHRM3 P20309 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
ADRA1A P35348 1/20 0.31
HRH1 P35367 1/20 0.31
DRD3 P35462 1/20 0.31
SLC6A3 Q01959 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
LAP3 P28838 2/20 0.31
ALDH1A1 P00352 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30049090 0.82 POLB (0.40) METAP1CYP2D6CYP2C9CYP2C19POLB
SCHEMBL7716778 0.77 CYP2D6 (0.39) METAP1CYP2D6CYP2C9CYP2C19POLB
SCHEMBL7717100 0.75 MMP8 (0.47) POLBLAP3ALDH1A1TSHR
SCHEMBL7718876 0.75 CYP2D6 (0.37) METAP1CYP2D6CYP2C9CYP2C19TDP1
SCHEMBL6132143 0.73 CYP2D6 (0.41) CYP2D6CYP2C9CYP2C19FDPSPOLB
SCHEMBL7715964 0.73 CYP2D6 (0.41) CYP2D6CYP2C9CYP2C19FDPSPOLB
SCHEMBL234751 0.71 ALDH1A1 (0.46) CYP2D6CYP2C9CYP2C19POLBTDP1
SCHEMBL235849 0.71 ALDH1A1 (0.50) ALDH1A1ALOX15TSHR
SCHEMBL3672437 0.71 POLB (0.56) METAP1CYP2D6CYP2C9CYP2C19FDPS
SCHEMBL7716769 0.71 CYP2D6 (0.42) CYP2D6CYP2C9CYP2C19LAP3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed